| Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors (NCT05194735) | Alaunos Therapeutics | 2022-04-04 |
| The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma (NCT06647836) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-01-01 |
| Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations (NCT04357873) | UNICANCER | 2020-10-28 |
| Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients (NCT04566432) | Geneplus-Beijing Co. Ltd. | 2020-07-01 |
| FGFR Inhibitor in FGFR Dysregulated Cancer (NCT03827850) | Lung Cancer Group Cologne | 2019-03-25 |
| Photodynamic Therapy for the Prevention of Lung Cancer (NCT03346304) | University College, London | 2018-09-01 |
| Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001 (NCT03574818) | Montefiore Medical Center | 2018-05-29 |
| Exhaled Breath Particles in Lung Cancer (NCT05395611) | Lund University Hospital | 2018-01-23 |
| Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC (NCT03177291) | H. Lee Moffitt Cancer Center and Research Institute | 2017-09-26 |
| An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) (NCT03823625) | Fondazione Ricerca Traslazionale | 2017-09-13 |
| GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression (NCT03198546) | Second Affiliated Hospital of Guangzhou Medical University | 2017-07-01 |
| Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China (NCT03059641) | Geneplus-Beijing Co. Ltd. | 2017-02-22 |
| Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor (NCT03041181) | Nasser Hanna, M.D. | 2017-01-27 |
| A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer (NCT02787473) | First People's Hospital of Hangzhou | 2016-10-01 |
| A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC (NCT02852083) | University Hospital Regensburg | 2016-01-01 |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers (NCT02583542) | Queen Mary University of London | 2015-06-01 |
| Icotinib for Completed Resected IB NSCLC With EGFR Mutation (NCT02264210) | Sun Yat-sen University | 2015-01-01 |
| Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer (NCT02288026) | Capital Medical University | 2014-09-01 |
| Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers (NCT02423590) | Queen Mary University of London | 2014-06-01 |
| Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC (NCT02059967) | Virginia Commonwealth University | 2014-03-01 |
| Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer (NCT01784640) | Jonsson Comprehensive Cancer Center | 2014-01-31 |
| Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens (NCT01948141) | Roswell Park Cancer Institute | 2014-01-30 |
| Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer (NCT01824901) | ECOG-ACRIN Cancer Research Group | 2014-01-15 |
| Autologous Natural Killer T Cells Infusion for the Treatment of Cancer (NCT01801852) | Chinese PLA General Hospital | 2013-01-01 |
| Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy (NCT01660399) | Tianjin Medical University Cancer Institute and Hospital | 2012-08-01 |
| Dasatinib in Advanced Squamous Cell Lung Cancer (NCT01491633) | Dana-Farber Cancer Institute | 2011-09-01 |
| Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer (NCT01383668) | Mayo Clinic | 2011-06-01 |
| Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery (NCT01345851) | Jonsson Comprehensive Cancer Center | 2011-03-23 |
| Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) (NCT01082549) | Sanofi | 2010-03-01 |
| Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer (NCT00909558) | Envita Medical Center, Inc. | 2009-05-01 |
| Pilot Study to Evaluate Optical Frequency Domain Imaging for Diagnosis of Central Airway Disease (NCT01396603) | Massachusetts General Hospital | 2008-12-01 |
| Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway Disease (NCT00784329) | Lahey Clinic | 2008-03-01 |
| Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NCT01557959) | Wake Forest University Health Sciences | 2007-07-01 |
| Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab (NCT00387374) | National Cancer Institute (NCI) | 2006-10-01 |
| S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer (NCT00368992) | National Cancer Institute (NCI) | 2006-08-01 |
| Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (NCT00118183) | National Cancer Institute (NCI) | 2005-07-01 |
| S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer (NCT00087412) | National Cancer Institute (NCI) | 2004-09-01 |
| Photodynamic Therapy in Treating Patients With Lung Cancer (NCT01668823) | Roswell Park Cancer Institute | 2004-02-01 |
| Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery (NCT00049543) | National Cancer Institute (NCI) | 2002-09-01 |
| Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer (NCT00040794) | National Cancer Institute (NCI) | 2002-05-01 |
| Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery (NCT00020709) | National Cancer Institute (NCI) | 2001-06-01 |
| Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery (NCT00005838) | National Cancer Institute (NCI) | 2000-03-01 |
| Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer (NCT00002852) | National Cancer Institute (NCI) | 1996-10-01 |